Yelp Inc. (YELP) Options Betting Picks Up on Pullback

Yelp Inc (YELP) is seeing options betting in the September series

by Alex Eppstein

Published on May 11, 2015 at 1:34 PM
Updated on May 11, 2015 at 1:34 PM

Yelp Inc (NYSE:YELP) is pulling back this afternoon, following last week's M&A-induced run-up. At last check, shares of the business review site are down 2.7% at $48.58. Meanwhile, both calls and puts are crossing at an above-average intraday rate.

The September series is seeing buy-to-open action at its 57.50 call and 48 put. The call buyers are anticipating YELP will bounce back -- and take out $57.50, territory not seen since early February -- by September options expiration. Meanwhile, the put buyers are counting on the stock to tumble south of $48 during the same time frame.

Today's negative price action is more of the same for YELP. Year-to-date, the shares have shed about 11%, and have been testing resistance at their descending 120-day moving average -- a trendline that has ushered the shares lower since last October.

Not everyone has caught on to this downward trajectory, though. In fact, the majority of analysts covering Yelp Inc (NYSE:YELP) maintain a "buy" or better rating on the shares, while the average 12-month price target of $56.26 stands at a nearly 16% premium to current trading levels. Should YELP continue to struggle, a round of downgrades and/or price-target cuts could translate into a fresh wave of selling pressure.

A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earning announcements before it's too late!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


The Latest Investor's Guide to Precious Metals
Learn how to protect savings and maximize returns by investing in precious metals.
Patent Lawsuit Loss Sends AMRN Stock Spiraling
Amarin just lost a major U.S. patent lawsuit for its heart drug Vascepa
RH Stock Sinks Despite Earnings Beat
J.P. Morgan Securities and Cowen and Company cut their price targets
The Latest Investor's Guide to Precious Metals
Learn how to protect savings and maximize returns by investing in precious metals.